The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELYM | +144.95% | N/A | N/A | -69% |
| S&P | +14.77% | +87.2% | +13.35% | +56% |
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.
No news articles found for Climb Bio.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$29.00K | 0.0% |
| Market Cap | $136.21M | -60.1% |
| Market Cap / Employee | $7.57M | 0.0% |
| Employees | 18 | 100.0% |
| Net Income | -$12,888.00K | -44.9% |
| EBITDA | -$14,863.00K | -77.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $25.80M | -82.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $352.00K | 0.0% |
| Short Term Debt | $228.00K | 293.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.09% | 16.2% |
| Return On Invested Capital | -45.35% | -0.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12,248.00K | -62.1% |
| Operating Free Cash Flow | -$12,139.00K | -60.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.55 | 0.39 | 0.43 | 0.73 | -52.06% |
| Price to Tangible Book Value | 0.55 | 0.39 | 0.43 | 0.73 | -52.06% |
| Price to Free Cash Flow TTM | 3785.71 | - | |||
| Enterprise Value to EBITDA | 2.69 | 0.66 | 0.02 | -3.39 | -80.76% |
| Free Cash Flow Yield | 0.0% | - | |||
| Return on Equity | -46.3% | -62.0% | -22.9% | -25.6% | -39.06% |
| Total Debt | $532.00K | $474.00K | $639.00K | $580.00K | 900.00% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
